Generic Medicine Info
Indications and Dosage
Adult: 50-100 mg 2-3 times daily.
Renal Impairment
Contraindicated in marked renal impairment.
Hepatic Impairment
Contraindicated in marked hepatic impairment.
Na or K depletion, adrenal gland failure, hyperchloraemic acidosis, and hepatic cirrhosis. Marked hepatic or renal impairment. Not to be used for long-term treatment of angle-closure glaucoma.
Special Precautions
Patient w/ pulmonary obstruction or emphysema, prediabetes or DM. Pregnancy and lactation.
Adverse Reactions
Paraesthesia, hearing dysfunction or tinnitus, fatigue, malaise, loss of appetite, taste alteration, GI disturbances (e.g. nausea, vomiting, diarrhoea), polyuria, drowsiness, confusion, metabolic acidosis, electrolyte imbalance, transient myopia, urticaria, melaena, haematuria, glycosuria, hepatic insufficiency, flaccid paralysis, photosensitivity, convulsions. Rarely, crystalluria and renal calculi.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias.
Monitoring Parameters
Monitor CBC, platelet count and serum electrolytes periodically.
Drug Interactions
Concomitant use w/ high-dose aspirin may result to anorexia, tachypnoea, lethargy, coma and death. Concomitant use w/ steroids may result to hypokalaemia.
Mechanism of Action: Methazolamide inhibits carbonic anhydrase resulting to decreased secretion of aqueous humour, thus decreasing intraocular pressure.
Onset: 2-4 hr.
Duration: 10-18 hr.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 1-2 hr.
Distribution: Distributed throughout the body including the plasma, CSF, aqueous humour of eye, RBC, bile and extra-cellular fluid. Volume of distribution: 17-23 L. Plasma protein binding: Approx 55%.
Metabolism: Partially metabolised hepatically.
Excretion: Via urine (approx 15-30%). Elimination half-life: Approx 14 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Methazolamide, CID=4100, (accessed on Jan. 22, 2020)

Store between 15-30°C.
MIMS Class
Antiglaucoma Preparations
Anon. Methazolamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/10/2014.

Buckingham R (ed). Methazolamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 03/10/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Methazolamide (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 03/10/2014.

Methazolamide Tablet (Effcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 03/10/2014.

Wickersham RM. Methazolamide. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/10/2014.

Disclaimer: This information is independently developed by MIMS based on Methazolamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in